| Literature DB >> 22389849 |
Dasharath M Patel1, Divyesh K Patel, Chhagan N Patel.
Abstract
Purpose. Effective Helicobacter pylori eradication requires delivery of the antibiotic locally in the stomach. High dose of amoxicillin (750 to 1000 mg) is difficult to incorporate in floating tablets but can easily be given in liquid dosage form. Keeping the above facts in mind, we made an attempt to develop a new floating in situ gelling system of amoxicillin with increased residence time using sodium alginate as gelling polymer to eradicate H. pylori. Methods. Floating in situ gelling formulations were prepared using sodium alginate, calcium chloride, sodium citrate, hydroxypropyl methyl cellulose K100, and sodium bicarbonate. The prepared formulations were evaluated for solution viscosity, floating lag time, total floating time, and in vitro drug release. The formulation was optimized using a 3(2) full factorial design. Dissolution data were fitted to various models to ascertain kinetic of drug release. Regression analysis and analysis of variance were performed for dependent variables. Results. All formulations (F(1)-F(9)) showed floating within 30 s and had total floating time of more than 24 h. All the formulations showed good pourability. It was observed that concentration of sodium alginate and HPMC K100 had significant influence on floating lag time, cumulative percentage drug release in 6 h and 10 h. The batch F(8) was considered optimum since it showed more similarity in drug release (f(2) = 74.38) to the theoretical release profile. Conclusion. Floating in situ gelling system of amoxicillin can be formulated using sodium alginate as a gelling polymer to sustain the drug release for 10 to 12 h with zero-order release kinetics.Entities:
Year: 2011 PMID: 22389849 PMCID: PMC3263723 DOI: 10.5402/2011/276250
Source DB: PubMed Journal: ISRN Pharm ISSN: 2090-6145
Formulation of amoxicillin in situ gel using different concentrations of calcium chloride and sodium citrate.
| Name of ingredient | Quantity in 100 mL (% w/v) | ||
|---|---|---|---|
|
|
|
| |
| Amoxicillin | 7.5 | 7.5 | 7.5 |
| Calcium chloride | 0.075 | 0.10 | 0.15 |
| Sodium citrate | 0.25 | 0.33 | 0.5 |
| Sodium alginate | 2.5 | 2.5 | 2.5 |
| HPMC K100 | 0.8 | 0.8 | 0.8 |
| Sodium bicarbonate | 1.5 | 1.5 | 1.5 |
| Deionised water | Q.S | Q.S | Q.S |
| Gelling strength | Open network gel | Open network gel | Close network Stiff gel |
| CPR | 100 (in 3 h) | 100 (in 5 h) | 70.14 (in 6 h) |
CPR indicates cumulative percentage release; HPMC K100 indicates hydroxypropyl methyl cellulose K100; Q.S indicates quantity sufficient.
Formulation of amoxicillin in situ gel using different concentrations of sodium bicarbonate.
| Name of ingredient | Quantity in 100 mL (% w/v) | ||
|---|---|---|---|
|
|
|
| |
| Amoxicillin | 7.5 | 7.5 | 7.5 |
| Calcium chloride | 0.15 | 0.15 | 0.15 |
| Sodium citrate | 0.5 | 0.5 | 0.5 |
| Sodium alginate | 2.5 | 2.5 | 2.5 |
| HPMC K100 | 0.8 | 0.8 | 0.8 |
| Sodium bicarbonate | 1 | 1.5 | 2 |
| Deionised water | Q.S | Q.S | Q.S |
| Floating lag time (s) | 55 | 48 | 30 |
| CPR at 6 h (%) | 67.50 | 71.57 | 82.84 |
CPR indicates cumulative percentage release; HPMC K100 indicates hydroxypropyl methyl cellulose K100; Q.S indicates quantity sufficient.
Formulation and evaluation of batches in 32 full factorial design.
| Batch code | Variable levels in coded form | FLT (s) |
|
|
|
| Viscosity (cps) | |
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
|
| −1 | −1 | 18 | 48.39 | 85.04 | 100.24 | 42.78 | 171.1 |
|
| −1 | 0 | 15 | 47.41 | 82.82 | 100.37 | 45.51 | 186.3 |
|
| −1 | 1 | 13 | 44.92 | 80.57 | 99.93 | 47.86 | 193.7 |
|
| 0 | −1 | 21 | 44.92 | 80.57 | 99.93 | 48.01 | 211.3 |
|
| 0 | 0 | 15 | 44.21 | 79.16 | 98.80 | 51.11 | 230.4 |
|
| 0 | 1 | 10 | 41.99 | 77.55 | 98.61 | 54.48 | 356.7 |
|
| 1 | −1 | 16 | 43.23 | 78.55 | 97.55 | 52.88 | 431.9 |
|
| 1 | 0 | 12 | 42.88 | 67.03 | 85.02 | 74.38 | 542.1 |
|
| 1 | 1 | 11 | 41.90 | 65.99 | 83.97 | 70.18 | 634.3 |
|
| ||||||||
| Coded values | Actual values | |||||||
|
|
| |||||||
|
| ||||||||
| −1 | 2% | 0.3% | ||||||
| 0 | 2.5% | 0.6% | ||||||
| 1 | 3% | 0.9% | ||||||
All batches contained 7.5% of amoxicillin, 1.5% of sodium bicarbonate, 0.15% of calcium chloride, and 0.5% of sodium citrate. X 1 indicates concentration of sodium alginate, X 2 concentration of HPMC K100. Q 1, Q 6, and Q 10 indicate percentage drug released after 1, 6, and 10 h, respectively. FLT indicates floating lag time; f 2 indicates similarity factor.
Summary of results of regression analysis.
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
| For FLT | ||||||
|
| ||||||
| Response (FLT) | ||||||
| FM | 14.77 | −1.16 | −3.5 | −3.4∗10−16 | −1.16 | 0.83 |
| RM | 14.56 | — | −3.5 | — | — | — |
|
| ||||||
| For | ||||||
|
| ||||||
| Response ( | ||||||
| FM | 44.11 | −2.12 | −1.29 | 0.53 | 1.09 | −0.69 |
| RM | — | — | — | — | — | — |
|
| ||||||
| For | ||||||
|
| ||||||
| Response ( | ||||||
| FM | 77.95 | −6.14 | −3.34 | −2.02 | −2.42 | 1.70 |
| RM | 77.47 | −6.14 | — | — | — | — |
|
| ||||||
| For | ||||||
|
| ||||||
| Response ( | ||||||
| FM | 97.79 | −5.66 | −2.53 | −3.31 | −4.6 | 1.97 |
| RM | 96.04 | −5.66 | — | — | — | — |
FM= Full model, RM= Reduced model; Q 1, Q 6, and Q 10 indicate percentage of drug released after 1, 6, and 10 h, respectively; FLT indicates floating lag time.
Calculations for testing the model in portions.
| DF | SS | MS |
|
| ||
|---|---|---|---|---|---|---|
| For floating lag time | ||||||
|
| ||||||
| Regression | ||||||
| FM | 5 | 85.77 | 17.15 | 4.13 | 0.87 |
|
| RM | 1 | 73.5 | 73.5 | 20.81 | 0.002 | |
| Error | ||||||
| FM | 3 | 12.44 | 4.15 | |||
| RM | 7 | 24.72 | 3.53 | |||
|
| ||||||
| For | ||||||
|
| ||||||
| Regression | ||||||
| FM | 5 | 327.42 | 65.48 | 8.71 | 0.935 |
|
| RM | 1 | 226.44 | 226.44 | 12.83 | 0.64 | |
| Error | ||||||
| FM | 3 | 22.54 | 7.51 | |||
| RM | 7 | 123.51 | 17.64 | |||
|
| ||||||
| For | ||||||
|
| ||||||
| Regression | ||||||
| FM | 5 | 325.37 | 65.07 | 7.83 | 0.92 |
|
| RM | 1 | 192.66 | 192.66 | — | 0.55 | |
| Error | ||||||
| FM | 3 | 12.44 | 4.15 | |||
| RM | 7 | 24.72 | 3.53 | |||
DF indicates the degree of freedom; SS: Sum of squares; MS: Mean of squares; R 2: Regression coefficient; FM: Full model; RM, Reduced model. Q 6 and Q 10 indicate percentage of drug released after 6 and 10 h, respectively.
Kinetic treatment of dissolution data.
|
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|
| Zero order | |||||||||
|
| 5.17 | 5.27 | 5.42 | 5.45 | 5.44 | 5.89 | 5.78 | 4.59 | 4.42 |
|
| 47.48 | 45.72 | 43.66 | 43.52 | 42.24 | 37.46 | 38.33 | 40.13 | 40.10 |
|
| 0.9619 | 0.9713 | 0.9716 | 0.9692 | 0.9771 | 0.9844 | 0.9811 | 0.9969 | 0.9941 |
| First order | |||||||||
|
| 0.030 | 0.031 | 0.033 | 0.033 | 0.033 | 0.036 | 0.035 | 0.029 | 0.029 |
|
| 1.699 | 1.686 | 1.668 | 1.667 | 1.657 | 1.619 | 1.626 | 1.637 | 1.634 |
|
| 0.9465 | 0.9554 | 0.9527 | 0.9496 | 0.9604 | 0.9702 | 0.9666 | 0.9874 | 0.9812 |
| Higuchi | |||||||||
|
| 24.07 | 24.42 | 25.13 | 25.31 | 25.14 | 27.02 | 26.50 | 20.73 | 20.04 |
|
| 22.88 | 20.91 | 18.09 | 17.74 | 16.81 | 10.41 | 11.76 | 19.70 | 20.54 |
|
| 0.9832 | 0.9880 | 0.9892 | 0.9877 | 0.9905 | 0.9893 | 0.9873 | 0.9897 | 0.9901 |
| Hixon Crowell | |||||||||
|
| −0.09 | −1.75 | −1.80 | −1.81 | −1.83 | −1.96 | −1.92 | −1.52 | −1.47 |
|
| 0.973 | 18.09 | 18.77 | 18.82 | 19.25 | 20.84 | 20.55 | 19.95 | 19.97 |
|
| −0.9525 | −0.9713 | −0.9715 | −0.9691 | −0.9775 | −0.9843 | −0.9810 | −0.9969 | −0.9940 |
| Korsemeyer and Peppas | |||||||||
|
| 0.333 | 0.341 | 0.361 | 0.364 | 0.363 | 0.396 | 0.387 | 0.316 | 0.313 |
|
| −0.34 | −0.355 | −0.376 | −0.378 | −0.385 | −0.423 | −0.416 | −0.395 | −0.399 |
|
| 0.9845 | 0.9857 | 0.9885 | 0.9868 | 0.9877 | 0.9802 | 0.9756 | 0.9832 | 0.9859 |
b = slope, a = intercept, R 2 = Square of correlation coefficient, and n = diffusion exponent.
Figure 1Comparison of dissolution profile.
Figure 2FTIR spectrum of amoxicillin.
Figure 4FTIR spectrum of amoxicillin and HPMC K100.
Figure 3FTIR spectrum of amoxicillin and HPMC K100.